MAM
STOK icon

Meeder Asset Management’s Stoke Therapeutics STOK Stock Holding History

Meeder Asset Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,387
Closed -$36K – 2196
2021
Q3 		$36K Hold
1,387
– – ﹤0.01% 1200
2021
Q2 		$47K Sell
1,387
-132
-9% -$4.67K ﹤0.01% 1151
2021
Q1 		$59K Buy
+1,519
New +$86.5K ﹤0.01% 1055

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Meeder Asset Management's STOK Position: Q4 2021 in Review

Meeder Asset Management sold out of Stoke Therapeutics (STOK) in Q4 2021, closing a stake of 1,387 shares — an estimated $36K sold.

Meeder Asset Management first reported a position in STOK in Q1 2021 and held it in 3 quarters. The position peaked at $59K in Q1 2021. 94 funds tracked by Wall St. Rank hold STOK as of Q4 2021.

  • Meeder Asset Management reported no remaining Stoke Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Meeder Asset Management sold 1,387 Stoke Therapeutics shares in Q4 2021, an estimated $36K.
  • Meeder Asset Management first reported a position in Stoke Therapeutics in Q1 2021 and held it in 3 quarters.
  • Meeder Asset Management's Stoke Therapeutics position peaked at $59K in Q1 2021.
  • 94 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q4 2021.

Based on Meeder Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.